WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbal 400 051
CIN: L24230MH1999PLC120720
Tel: 91 22 2653 4444; Fax: 91 22 2652 3905; e-mail id: investorrelations@wockhardt.com; Website: www.wockhardt.com

|       | STATEMENT OF CONSOLIDATED UNAUDITED R   |                                 |                                 |                                 |                                 |                                 |                        |
|-------|---|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|------------------------|
|       | PARTICULARS   | 3 MONTHS<br>ENDED<br>30/09/2017 | 3 MONTHS<br>ENDED<br>30/06/2017 | 3 MONTHS<br>ENDED<br>30/09/2016 | 6 MONTHS<br>ENDED<br>30/09/2017 | 6 MONTHS<br>ENDED<br>30/09/2016 | 31/03/2017             |
|       | (Refer Notes Below)   | Unaudited                       | Unaudited                       | Unaudited                       | Unaudited                       | Unaudited                       | Audited                |
| a) Re | evenue from Operations  | 102,228                         | 89,106                          | 106,469                         | 191,334                         | 215,552                         | 401,46                 |
|       | ther Income   | 5,455<br><b>107,683</b>         | 3,702<br><b>92,808</b>          | 1,864<br><b>108,333</b>         | 9,157<br><b>200,491</b>         | 3,554<br><b>219,106</b>         | 11,42<br><b>412,88</b> |
| Expe  | enses   |                                 |                                 |                                 |                                 |                                 |                        |
|       | Cost of materials consumed  | 18,746                          | 22,055                          | 22,442                          | 40,801                          | 49,015                          | 89,19                  |
| (c) C | Purchase of Stock-in-trade<br>Changes in inventories of finished goods, work-in-progress and  | 18,672                          | 15,014                          | 20,186                          | 33,686                          | 37,239                          | 79,60                  |
|       | k-in-trade  | 9,756                           | 4,244                           | (3,390)                         | 14,000                          | (5,327)                         | (2,58                  |
|       | Employee benefits expense   | 24,925                          | 23,844                          | 24,618                          | 48,769                          | 49,743                          | 96,6                   |
|       | Finance Costs   | 6,760                           | 6,111                           | 5,637                           | 12,871                          | 10,495<br>864                   | 22,5<br>1,3            |
|       | exchange fluctuation (gain) / loss  | (1,286)<br>3,619                | (1,927)<br>3,718                | (126)<br>3,736                  | (3,213)<br>7,337                | 7,374                           | 14,8                   |
|       | Depreciation and amortisation expense   | 29,284                          | 31.883                          | 32,662                          | 61,167                          | 66,407                          | 135,9                  |
|       | Other expenses  | 110,476                         | 104.942                         | 105,765                         | 215,418                         | 215,810                         | 437.60                 |
|       | fit / (Loss) before exceptional items and tax (1-2)   | (2,793)                         | (12,134)                        | 2,568                           | (14,927)                        | 3,296                           | (24,71                 |
|       | eptional Items (gain) / loss (Refer Note 4)   | (2,100)                         | 35.819                          | 2,000                           | 35,819                          | 0,200                           | 12-11-                 |
|       | Profit / (Loss) before tax (3 ± 4)  | (2.793)                         | (47,953)                        | 2,568                           | (50,746)                        | 3,296                           | (24.71                 |
|       | Expense:  | 32,001                          | 111,141,17                      |                                 | 377                             |                                 |                        |
|       | urrent tax  | (1,401)                         | (193)                           | (831)                           | (1,594)                         | (1,110)                         | (1,03                  |
|       | eferred tax credit/ (charge)  | 3,312                           | 1,889                           | 755                             | 5,201                           | 1,976                           | 3,1                    |
| Net   | Profit / (Loss) after tax (5 ± 6)   | (882)                           | (46,257)                        | 2,492                           | (47,139)                        | 4,162                           | (22,60                 |
| Shar  | re of Profit/(Loss) of Associate  |                                 | -                               |                                 | 5                               |                                 |                        |
| Non   | - Controlling Interest  | (549)                           | (5,291)                         | 790                             | (5,840)                         | 871                             | (3,03                  |
|       | Profit/(Loss) after taxes, non-controlling interest and share rofit / (loss) of associates (7 ± 8 ± 9)                                      | (333)                           | (40,966)                        | 1,702                           | (41,299)                        | 3,291                           | (19,57                 |
| Othe  | er Comprehensive Income   |                                 |                                 |                                 |                                 |                                 |                        |
|       | ems that will not be reclassified to Profit or Loss (consisting of<br>neasurement of net defined benefit liability / asset;                 | 2,109                           | 441                             | (809)                           | 2,550                           | (1,604)                         | (3,36                  |
| b) In | ncome tax relating to items that will not be reclassified to Profit oss   | (197)                           | (30)                            | 83                              | (227)                           | 165                             | 38                     |
| Exch  | ems that will be reclassified to Profit or Loss (Consisting of hange differences on translating the financial statements of ign operations) | 4,118                           | 3,673                           | (6,898)                         | 7,791                           | (6,825)                         | (15,17                 |
|       | other comprehensive income (net of tax) (11a ± 11b ± 11c)   | 6,030                           | 4,084                           | (7,624)                         | 10,114                          | (8,264)                         | (18,15                 |
| Tota  | al Comprehensive Income (7 ± 8 ± 11 (d))  | 5,148                           | (42,173)                        | (5,132)                         | (37,025)                        | (4,102)                         | (40,76                 |
|       | butable to Equity shareholders of the Company   | 4,818                           | (37,466)                        | (4,845)                         | (32,648)                        | (3,808)                         | (35,22                 |
| 1.0   | butable to Non Controlling Interest   | 330                             | (4,707)                         | (287)                           | (4,377)                         | (294)                           | (5,53                  |
| 11.00 | d-up equity share capital (face value Rs. 5/- each)   | 5,528                           | 5,528                           | 5,527                           | 5,528                           | 5,527                           | 5,5                    |
|       | er Equity excluding Revaluation Reserves as per balance sheet   | -,520                           | -,520                           | -,-2.                           | -,,,,,                          |                                 | 328,1                  |
|       | nings Per Share (face value of Rs. 5 each) (*Not Annualised)  |                                 |                                 |                                 |                                 |                                 |                        |
|       | Basic (Rs.)   | (0.30)*                         | (37.06)*                        | 1.54*                           | (37.36)*                        | 2 98*                           | (17.                   |
| , ,   | Diluted (Rs.)   | (0.30)*                         | (37.72)*                        | 1.53*                           | (37.36)*                        | 2.95*                           | (17.                   |





#### Notes To Consolidated Results:-

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on October 30, 2017. The results have been subjected to limited review by the Statutory Auditors of the Company.
- 2) These Consolidated Results relate to Wockhardt Limited ('the Holding Company') and its Subsidiaries (together constitute 'the Group') and are prepared by applying Ind AS 110 "Consolidated Financial Statements"

3) Key Financials on Standalone basis:

| Particulars                        | 3 MONTHS<br>ENDED<br>30/09/2017 | 3 MONTHS<br>ENDED<br>30/06/2017 | 3 MONTHS<br>ENDED<br>30/09/2016 | 6 MONTHS<br>ENDED<br>30/09/2017 | 6 MONTHS<br>ENDED<br>30/09/2016 | YEAR ENDED<br>31/03/2017 |
|------------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|--------------------------|
|                                    | Unaudited                       | Unaudited                       | Unaudited                       | Unaudited                       | Unaudited                       | Audited                  |
| Net Sales / Income from operations | 58,893                          | 43,990                          | 59,828                          | 102,883                         | 121,163                         | 229,752                  |
| Profit / (Loss) Before Tax         | (381)                           | (12,446)                        | 14,165                          | (12,827)                        | 14,333                          | 11,878                   |
| Profit / (Loss) After Tax          | 2,532                           | (10,158)                        | 14,616                          | (7,626)                         | 16,249                          | 13,712                   |

Note: The Unaudited stand alone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com) and also on the Company's website www.wockhardt.com.

Exceptional item: During the quarter ended June 30, 2017, the on-going commercial litigation between the Company and two of its subsidiaries namely Wockhardt UK Holdings Limited and CP Pharmaceuticals Limited (CP) in relation to a supply contract with Cephalon Inc, (Cephalon) an affiliate of Teva Pharmaceuticals USA, Inc. (Teva) before the High Court in London, United Kingdom, was settled at cost of GBP 43 mn to the Group.

The High Court has accepted the settlement between the parties and a Consent Order was issued on June 21, 2017. Pursuant to this settlement the ongoing litigation stands closed.

- 5) The Group is exclusively into Pharmaceutical business Segment.
- 6) For list of Subsidiaries as on September 30, 2017 please refer Annexure.
- Previous periods / year figures have been recast / regrouped to conform to the current period's presentation.

FOR WOCKHARDT LIMITED

Mumbai Date: October 30, 2017 H F KHORAKIWALA CHAIRMAN

DIN: 00045608





## **WOCKHARDT LIMITED**

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006 Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

# STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES

(Rs. in Lakhs)

|    | (Rs. in Lak  |                             |                              |  |  |
|----|--|-----------------------------|------------------------------|--|--|
|    | PARTICULARS  | As at Period End 30/09/2017 | As at Year End<br>31/03/2017 |  |  |
|    |  | Unaudited                   | Audited                      |  |  |
| 4) | ASSETS   |                             |                              |  |  |
| 1  | Non- current assets  |                             |                              |  |  |
|    | (a) Property, Plant and Equipment                              | 191,599                     | 194,20                       |  |  |
|    | (b) Capital work-in-progress                                   | 102,255                     | 97,12                        |  |  |
|    | (c) Goodwill   | 80,641                      | 73,65                        |  |  |
|    |  |                             |                              |  |  |
|    | (d) Other Intangible assets                                    | 9,118                       | 9,39                         |  |  |
|    | (e) Intangible assets under development                        | 32,508                      | 27,26                        |  |  |
|    | (f) Financial assets   |                             |                              |  |  |
|    | (i) Other investments  | 45                          | 4                            |  |  |
|    | (ii) Other non- current Financial assets                       | 4,979                       | 4,85                         |  |  |
|    | (g) Deferred tax assets (net)                                  | 24,076                      | 17,28                        |  |  |
|    | (h) Other non-current assets                                   | 9,036                       | 11,42                        |  |  |
|    | (ii) Other Hon-current assets                                  | 5,000                       | 11,72                        |  |  |
|    | Sub-total - Non-current assets                                 | 454,257                     | 435,26                       |  |  |
| 2  | Current assets   |                             | 440 =                        |  |  |
|    | (a) Inventories  | 93,741                      | 110,79                       |  |  |
|    | (b) Financial assets   | I                           |                              |  |  |
|    | (i) Investments  | 67,277                      | 56,22                        |  |  |
|    | (ii) Trade receivables   | 97,378                      | 103,44                       |  |  |
|    | (iii) Cash and cash equivalents                                | 36,004                      | 96,56                        |  |  |
|    | (iv) Bank balance [other than (iii) above]                     | 55,447                      | 63,79                        |  |  |
|    | (v) Other current Financial assets                             | 545                         | 2,92                         |  |  |
|    |  |                             |                              |  |  |
|    | (c) Current Tax Assets (net)                                   | 9,001                       | 8,07                         |  |  |
|    | (d) Other current assets                                       | 23,880                      | 19,77                        |  |  |
|    | Sub-total - Current assets                                     | 383,273                     | 461,60                       |  |  |
|    | TOTAL ASSETS   | 837,530                     | 896,86                       |  |  |
| 3) | EQUITY AND LIABILITIES   |                             |                              |  |  |
| 1  | Equity   |                             |                              |  |  |
|    | (a) Equity share capital                                       | 5,528                       | 5,52                         |  |  |
|    | (b) Other Equity   | 295,121                     | 328,14                       |  |  |
|    | 200  | 300.649                     | 333,67                       |  |  |
|    | Equity attributable to the share holders of the Company        |                             |                              |  |  |
|    | (c) Non - Controlling Interest                                 | 33,817                      | 38,19                        |  |  |
|    | Sub-total- Equity  | 334,466                     | 371,86                       |  |  |
| _  | Liabilities Non- Current liabilities (a) Financial liabilities |                             |                              |  |  |
|    | Borrowings   | 286,928                     | 319.02                       |  |  |
|    | (b) Provisions   | 7,811                       | 9.42                         |  |  |
|    | (c) Deferred tax liabilities (net)                             | 5,367                       | 3,97                         |  |  |
|    | Sub-total- Non-current liabilities                             | 300,106                     | 332,42                       |  |  |
| П. | Current liabilities (a) Financial liabilities                  |                             |                              |  |  |
|    | (i) Borrowings   | 57,799                      | 66,05                        |  |  |
|    | (ii) Trade payables  | 45,931                      | 53,38                        |  |  |
|    | (iii) Other financial liabilities                              | 89,947                      | 65,50                        |  |  |
|    | (b) Other current liabilities                                  | 5,228                       | 3,73                         |  |  |
|    | ILDI OLI EL CUITETIL HADIILIES                                 |                             | 3,90                         |  |  |
|    | 1, ,   |                             |                              |  |  |
|    | (c) Provisions   | 4,053<br><b>202.95</b> 8    |                              |  |  |
|    | 1, ,   | 4,053<br>202,958<br>837,530 | 192,58<br>896,86             |  |  |

FOR WOCKHARDT LIMITED

Mumbai Date : October 30, 2017

TD.

H F KHORAKIWALA CHAIRMAN

DIN: 00045608

#### WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006 Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

## Annexure to Note 6 of Consolidated Unaudited Results for the Quarter and Six months ended September 30, 2017

## List of Subsidiaries as on September 30,2017

- 1 Wockhardt Infrastructure Development Limited
- 2 Wockhardt UK Holdings Limited
- 3 Wockhardt Blo AG [Formerly, Wockhardt EU Operations (Swiss) AG]
- 4 Wockhardt Europe Limited
- 5 CP Pharmaceuticals Limited
- 6 Wallis Group Limited
- 7 The Wallis Laboratory Limited
- 8 Wallis Licensing Limited
- 9 Wockhardt Farmaceutica Do Brasil Ltda
- 10 Z & Z Services GmbH (formerly, Esparma GmbH)
- 11 Wockhardt UK Limited
- 12 CP Pharma (Schweiz) AG
- 13 Wockpharma Ireland Limited
- 14 Pinewood Healthcare Limited
- 15 Pinewood Laboratories Limited
- 16 Wockhardt France (Holdings) S.A.S.
- 17 Niverpharma S.A.S.
- 18 Laboratoires Pharma 2000 S.A.S.
- 19 Laboratoires Negma S.A.S.
- 20 Negma Beneulex S.A.
- 21 Phytex S.A.S.
- 22 Wockhardt Holding Corp
- 23 Morton Grove Pharmaceuticals Inc.
- 24 MGP Inc
- 25 Wockhardt USA LLC
- 26 Wockhardt Farmaceutica SA DE CV
- 27 Wockhardt Services SA DE CV
- 28 Wockhardt Nigeria Limited
- 29 Wockhardt Bio [R]
- 30 Wockhardt Bio Pty Ltd
- 31 Wockhardt Bio Ltd





WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
CIN:124230MH1999PLC120720

Tel: 91 22 2653 4444 ; Fax: 91 22 2652 3905; e-mail id: investorrelations@wockhardt.com; Website: www.wockhardt.com

|       | PARTICULARS  | 3 MONTHS<br>ENDED<br>30/09/2017 | 3 MONTHS<br>ENDED<br>30/06/2017 | 3 MONTHS<br>ENDED<br>30/09/2016 | 6 MONTHS<br>ENDED<br>30/09/2017 | 6 MONTHS<br>ENDED<br>30/09/2016 | YEAR ENDED<br>31/03/2017 |
|-------|--|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|--------------------------|
|       | (Refer notes below)  | Unaudited                       | Unaudited                       | Unaudited                       | Unaudited                       | Unaudited                       | Audited                  |
| 1 (a) | ) Revenue from operations  | 58,893                          | 43,990                          | 59,828                          | 102,883                         | 121,163                         | 229,75                   |
|       | ) Other income   | 1,223                           | 2,250                           | 19,103                          | 3,473                           | 20,839                          | 24,83                    |
|       | otal income  | 60,116                          | 46,240                          | 78.931                          | 106.356                         | 142,002                         | 254,58                   |
|       | penses   |                                 |                                 | 1.547.1                         |                                 | 117/13                          |                          |
|       | ) Cost of materials consumed   | 9.372                           | 11.721                          | 14.091                          | 21.093                          | 29.883                          | 53.52                    |
|       | ) Purchase of stock-in-trade   | 10,131                          | 7,167                           | 12,974                          | 17,298                          | 23,316                          | 42,86                    |
|       | Changes in inventories of finished goods, work-in-progress           | ,                               | .,                              | ,                               | ,===                            | ,                               | ,_,                      |
|       | d stock-in-trade   | 7,293                           | 2,809                           | (1,664)                         | 10,102                          | (3,473)                         | (1,43                    |
| (d)   | ) Employee benefits expense  | 12,816                          | 13,094                          | 12,991                          | 25,910                          | 26,356                          | 52,32                    |
| (e)   | ) Finance costs  | 4,350                           | 4,292                           | 4,231                           | 8,642                           | 8,643                           | 16,87                    |
| (f)   | Depreciation and amortisation expense                                | 2,573                           | 2,654                           | 2,689                           | 5,227                           | 5,262                           | 10,56                    |
| (g)   | ) Exchange fluctuation (gain) / loss                                 | 168                             | 304                             | 246                             | 472                             | 137                             | (1,14                    |
|       | Other expenses   | 13,794                          | 16,645                          | 19,208                          | 30,439                          | 37,545                          | 69,1                     |
| To    | otal expenses  | 60,497                          | 58,686                          | 64,766                          | 119,183                         | 127,669                         | 242,7                    |
| Pr    | ofit / (Loss) before tax (1-2)                                       | (381)                           | (12,446)                        | 14,165                          | (12,827)                        | 14,333                          | 11,8                     |
| Ta    | x expense:   |                                 |                                 |                                 |                                 |                                 |                          |
| Cu    | urrent tax   | -                               | : :                             | (3,273)                         | 2.00                            | (3,455)                         | (2,53                    |
| De    | eferred tax credit/(charge)  | 2,913                           | 2,288                           | 3,724                           | 5,201                           | 5,371                           | 4,30                     |
| Ne    | et Profit / (Loss) after tax (3 ± 4)                                 | 2,532                           | (10,158)                        | 14,616                          | (7,626)                         | 16,249                          | 13,7                     |
| Ot    | her Comprehensive Income   |                                 |                                 |                                 |                                 |                                 |                          |
|       | Items that will not be reclassified to Profit or Loss (consisting of | (60)                            | (60)                            | (22)                            | (120)                           | (44)                            | (24                      |
| re-   | -measurement of net defined benefit liability/asset)                 |                                 |                                 |                                 |                                 |                                 |                          |
|       | Income tax relating to items that will not be reclassified to Profil | 20                              | 20                              | 7                               | 40                              | 14                              |                          |
|       | Loss   |                                 |                                 |                                 |                                 |                                 |                          |
| c)    | Other Comprehensive Income (net of tax) (6a ± 6b)                    | (40)                            | (40)                            | (15)                            | (80)                            | (30)                            | (16                      |
|       | otal Comprehensive Income (5 ± 6c)                                   | 2,492                           | (10,198)                        | 14,601                          | (7,706)                         | 16,219                          | 13,5                     |
|       | aid-up equity share capital (face value of Rs. 5/- each)             | 5,528                           | 5,528                           | 5,527                           | 5,528                           | 5,527                           | 5,5                      |
|       | ther Equity excluding Revaluation Reserves as per balance eet        |                                 |                                 |                                 |                                 |                                 | 116,4                    |
|       | amings per share (face value of Rs. 5/- each) (*not annualised)      |                                 |                                 |                                 |                                 |                                 |                          |
|       | ) Basic (Rs.)  | 2.29*                           | (9.19)*                         | 13.22*                          | (6.90)*                         | 14.70*                          | 12.4                     |
| (b)   | ) Diluted (Rs.)  | 2.26*                           | (9.99)*                         | 13.12*                          | (6.90)*                         | 14.59*                          | 12.2                     |





## Notes To Standalone Results :-

- The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on October 30, 2017. The results have been subjected to limited review by the Statutory Auditors of the Company.
- 2) The Company is exclusively into Pharmaceutical business Segment
- 3) Previous period / year figures have been recast / re-grouped to conform to the current period's presentation

FOR WOCKHARDT LIMITED

H F KHORAKIWALA CHAIRMAN DIN: 00045608

Mumbai Date : October 30, 2017





## **WOCKHARDT LIMITED**

Registered Office: D-4 MIDC, Chikalithana, Aurangabad - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

# STATEMENT OF STANDALONE ASSETS AND LIABILITIES

(Rs. in Lakhs)

|      |   | (Rs. in Lakhs)                              |   |  |  |
|------|---|---|---|--|--|
|      | PARTICULARS   | As at Period End<br>30/09/2017<br>Unaudited | As at Year End<br>31/03/2017<br>Audited |  |  |
| ()   | ASSETS  |   |   |  |  |
| - 4  | Non- current assets   |   |   |  |  |
|      |   | 140,882                                     | 143,790                                 |  |  |
| - 1  | (a) Property, Plant and Equipment                               | 67,696                                      | 66,534                                  |  |  |
|      | (b) Capital work-in-progress                                    | 2,610                                       | 2,66                                    |  |  |
|      | (c) Intangible assets   | 2,610                                       | ∠,00                                    |  |  |
| - (  | (d) Financial assets  | 00.077                                      | 20.07                                   |  |  |
|      | (i) Investments in subsidiaries                                 | 29,677                                      | 29,67                                   |  |  |
|      | (ii) Other Investments  | 45  | 4                                       |  |  |
|      | (iii) Other non- current Financial assets                       | 6,607                                       | 5,76                                    |  |  |
| - 10 | (e) Deferred tax assets (net)                                   | 11,040                                      | 5,80                                    |  |  |
| 1    | (f) Other non-current assets                                    | 10,368                                      | 11,01                                   |  |  |
|      | Sub-total- Non-current assets                                   | 268,925                                     | 265,28                                  |  |  |
| 2    | Current assets  |   |   |  |  |
| - 1  | (a) Inventories   | 39,739                                      | 53,47                                   |  |  |
| - 1  |   | 39,739                                      | 30,77                                   |  |  |
| 1    | (b) Financial assets  | 42,999                                      | 34,28                                   |  |  |
|      | (i) Trade receivables   | 8,323                                       | 2,35                                    |  |  |
| - 1  | (ii) Cash and cash equivalents                                  |   |   |  |  |
|      | (iii) Bank balance (other than (ii) above)                      | 41,962                                      | 63,61                                   |  |  |
|      | (iv) Loans given  | 236   | 92                                      |  |  |
|      | (v) Other current Financial assets                              | 598   | 6,00                                    |  |  |
|      | (c) Current Tax Assets (Net)                                    | 9,230                                       | 8,72                                    |  |  |
| - 1  | (d ) Other current assets                                       | 19,079                                      | 19,02                                   |  |  |
|      | Sub-total - Current assets                                      | 162,166                                     | 188,40                                  |  |  |
|      | TOTAL ASSETS  | 431,091                                     | 453,68                                  |  |  |
| )    | EQUITY AND LIABILITIES  |   |   |  |  |
| 1    | Equity  |   |   |  |  |
|      | (a) Equity share capital  | 5,528                                       | 5,52                                    |  |  |
| - 1  | (b) Other Equity  | 109,031                                     | 116,40                                  |  |  |
|      | Sub-total- Equity   | 114,559                                     | 121,93                                  |  |  |
|      |   |   |   |  |  |
| 2    | Liabilities   |   |   |  |  |
| 1.   | Non- Current liabilities  |   |   |  |  |
| -    | (a) Financial liabilities                                       |   |   |  |  |
| - 1  | Borrowings  | 118,865                                     | 128,26                                  |  |  |
| Į,   | (b) Provisions  | 5,017                                       | 4,61                                    |  |  |
| - 1  | (c) Other non-current liabilities                               | 43,796                                      | 42,66                                   |  |  |
|      | Sub-total- Non-current liabilities                              | 167,678                                     | 175,54                                  |  |  |
| 11.  | Current liabilities   |   |   |  |  |
|      | (a) Financial liabilities                                       |   |   |  |  |
|      | (i) Borrowings  | 57,799                                      | 65,96                                   |  |  |
|      | (i) Borrowings<br>(ii) Trade payables                           | 34,686                                      | 34,63                                   |  |  |
| - 1  | 1,7   | 37,103                                      | 30,44                                   |  |  |
| - 1  | (iii) Other financial liabilities (b) Other current liabilities | 15,461                                      | 21,64                                   |  |  |
|      | (D) Other current liabilities                                   | 3,805                                       | 3,52                                    |  |  |
|      | A-1   |   | J.02                                    |  |  |
|      | (c) Provisions Sub-total- Current liabilities                   | 148,854                                     | 156,21                                  |  |  |
|      | (c) Provisions  |   |   |  |  |

Mumbai

Date: October 30, 2017



FOR WOCKHARDT LIMITED

H F KHORAKIWALA CHAIRMAN DIN: 00045608